{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:13:42Z","timestamp":1788556422964,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"DOI":"10.1007\/s00120-026-02922-4","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:30:11Z","timestamp":1788553811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immun-Checkpoint-Inhibition plus Bacillus Calmette-Guerin (BCG) beim BCG-naiven High-risk-NMIBC (nicht-muskelinvasives Urothelkarzinom der Blase): Ein kritischer Review im Kontext der aktuellen Evidenzlage","Immune checkpoint inhibition plus Bacillus Calmette\u2013Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a\u00a0critical review in the context of current evidence"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-2406","authenticated-orcid":false,"given":"Georgios","family":"Gakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"vom Dorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"5","key":"2922_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1046\/j.1464-410X.1997.00431.x","volume":"80","author":"HW Herr","year":"1997","unstructured":"Herr\u00a0HW (1997) Tumor progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 80(5):762\u2013765","journal-title":"Br J Urol"},{"issue":"2","key":"2922_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","volume":"75","author":"EJ Pietzak","year":"2019","unstructured":"Pietzak\u00a0EJ, Zabor\u00a0EC, Bagrodia\u00a0A et\u00a0al (2019) Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a\u00a0basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. Eur Urol 75(2):231\u2013239","journal-title":"Eur Urol"},{"issue":"5","key":"2922_CR3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"MO Grimm","year":"2020","unstructured":"Grimm\u00a0MO, van der Heijden\u00a0AG, Colombel\u00a0M et\u00a0al (2020) Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation randomized phase\u00a0III clinical trial \u201cNIMBUS\u201d. Eur Urol 78(5):690\u2013698","journal-title":"Eur Urol"},{"issue":"4","key":"2922_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm\u00a0DL, Blumenstein\u00a0BA, Crissman\u00a0JD et\u00a0al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a\u00a0randomized Southwest Oncology Group Study. J\u00a0Urol 163(4):1124\u20131129","journal-title":"J Urol"},{"issue":"4","key":"2922_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamaoncol.2023.6804","volume":"10","author":"AB Katims","year":"2024","unstructured":"Katims\u00a0AB, Tallman\u00a0J, Vertosick\u00a0E et\u00a0al (2024) Response to 2\u00a0induction courses of Bacille-Calmette-Guerin therapy among patients with high-risk non-muscle-invasive bladder cancer: 5\u2011years follow-up of a\u00a0phase\u00a02 clinical trial. JAMA Oncol 10(4):522\u2013525","journal-title":"JAMA Oncol"},{"issue":"5","key":"2922_CR6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","volume":"61","author":"RE Hautmann","year":"2012","unstructured":"Hautmann\u00a0RE, de Petriconi\u00a0RC, Pfeiffer\u00a0C, Volkmer\u00a0BG (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy; long-term results in 1100 patients. Eur Urol 61(5):1039\u20131047","journal-title":"Eur Urol"},{"issue":"7","key":"2922_CR7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar\u00a0AV, Kamat\u00a0AM, Kulkarni\u00a0GS et\u00a0al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 22(7):919\u2013928","journal-title":"Lancet Oncol"},{"issue":"1","key":"2922_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","volume":"37","author":"M Roupret","year":"2026","unstructured":"Roupret\u00a0M, Bertaut\u00a0A, Pignot\u00a0G et\u00a0al (2026) ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). Ann Oncol 37(1):44\u201352","journal-title":"Ann Oncol"},{"issue":"10516","key":"2922_CR9","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","volume":"406","author":"M De Santis","year":"2025","unstructured":"De Santis\u00a0M, Palou Redorta\u00a0J, Nishiyama\u00a0H et\u00a0al (2025) Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet 406(10516):2221\u20132234","journal-title":"Lancet"},{"issue":"8","key":"2922_CR10","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","volume":"31","author":"ND Shore","year":"2025","unstructured":"Shore\u00a0ND, Powles\u00a0TB, Bedke\u00a0J et\u00a0al (2025) Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med 31(8):2806\u20132814","journal-title":"Nat Med"},{"issue":"16","key":"2922_CR11","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat\u00a0AM, Sylvester\u00a0RJ, B\u00f6hle\u00a0A et\u00a0al (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J\u00a0Clin Oncol 34(16):1935\u20131944","journal-title":"J Clin Oncol"},{"key":"2922_CR12","unstructured":"Shore ND, Nishiyama H, Palou Redorta J et\u00a0al. (2026) Durvalumab in combination with BCG induction and maintenance therapy for BCG-naive, high-risk non\u2013muscle-invasive bladder cancer: expanded efficacy and safety analyses from POTOMAC. Presented at the American Urological Association (AUA) Annual Meeting, May 15\u201318, 2026, Washington, DC (Abstract \/ Presentation)"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02922-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02922-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02922-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:30:12Z","timestamp":1788553812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02922-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":12,"alternative-id":["2922"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02922-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.\u00a0Gakis:\n                      Vortragst\u00e4tigkeit:\n                      Astra Zeneca, Erbe Elektromedizin, Bristol-Myers Squibb, IPSEN Pharma, Leo Pharma, medac, Merck, MSD, Roche, CEA Alliance, Johnson & Johnson, Pfizer, Solution Akademie;\n                      Beratert\u00e4tigkeit:\n                      Astellas, Astra Zeneca, Johnson & Johnson, Bristol-Myers Squibb, IPSEN Pharma, Bayer, Pfizer, Roche, Leo Pharma, medac, Merck Serono, Merck, MSD, QED Therapeutics, Photocure;\n                      Kongressunterst\u00fctzung:\n                      Astellas, Astra Zeneca, IPSEN Pharma, Leo Pharma, MSD, Johnson & Johnson, Pfizer, Astellas, Bristol-Myers Squibb, Photocure, Merck, MSD, Merck;\n                      Forschungsunterst\u00fctzung:\n                      Photocure. F.\u00a0vom Dorp gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Die Analyse erfolgte auf Basis bereits publizierter Daten und unterliegt den Grunds\u00e4tzen der Deklaration von Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}